@article{ZHANG2026, 
author = {Yanru ZHANG and Qiuyue TU and Ping WANG and Zelin FENG and Huizhen LI and Yushan ZHU and Haojia LIN and Xinyue WEI and Qinghua YI and Hetong ZHANG and Yueting LI and Xiaoqin LI and Yu WANG and Dong XIE and Xiaocang CAO},
title = {Research Progress on the Risk of Excipients-Related Adverse Reactions in Pharmaceutical Preparations for IBD Treatment},
year = {2026},
journal = {Medical Journal of Peking Union Medical College Hospital},
volume = {17},
number = {4},
pages = {1135-1142},
keywords = {inflammatory bowel disease, pharmaceutical excipients, adverse reactions, clinical management, preventive strategies},
url = {https://www.sciopen.com/article/10.12290/xhyxzz.2025-0748},
doi = {10.12290/xhyxzz.2025-0748},
abstract = {Patients with inflammatory bowel disease (IBD) require long-term pharmacotherapy. Due to the wide variety of clinically available drugs, medication safety has become increasingly concerning. As an indispensable component of pharmaceutical formulations, drug excipients may induce various adverse reactions, including rash, allergic responses, and gastrointestinal discomfort, and may even lead to severe organic injury. However, they are often overlooked in clinical practice. Therefore, identifying and managing excipient-related adverse reactions is crucial for ensuring medication safety. To address this issue, this article systematically reviews common excipients in IBD therapeutics, the underlying mechanisms of excipient-induced adverse reactions, and corresponding management strategies, aiming to enhance clinicians' awareness of excipient-related issues, improve their ability to recognize and manage such reactions, and ultimately ensure patient safety.}
}